➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Merck
Baxter
Boehringer Ingelheim
Johnson and Johnson
Moodys

Last Updated: May 18, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Losmapimod

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Losmapimod?

Losmapimod is an investigational drug.

There have been 12 clinical trials for Losmapimod. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2020.

The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Muscular Dystrophy, Facioscapulohumeral, and Lung Diseases, Obstructive. The leading clinical trial sponsors are GlaxoSmithKline, Fulcrum Therapeutics, and Cambridge University Hospitals NHS Foundation Trust.

There are one hundred and six US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Losmapimod
TitleSponsorPhase
Losmapimod Safety and Efficacy in COVID-19Fulcrum TherapeuticsPhase 3
Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)Fulcrum TherapeuticsPhase 2
Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)Fulcrum TherapeuticsPhase 2

See all Losmapimod clinical trials

Clinical Trial Summary for Losmapimod

Top disease conditions for Losmapimod
Top clinical trial sponsors for Losmapimod

See all Losmapimod clinical trials

US Patents for Losmapimod

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Losmapimod   Get Started Free Compounds .alpha..sub.v.beta..sub.6 integrin antagonists GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB)   Get Started Free
Losmapimod   Get Started Free IBAT inhibitors for the treatment of liver diseases Albireo AB (Gothenburg, SE)   Get Started Free
Losmapimod   Get Started Free Compounds alpha v beta 6 integrin antagonists GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB)   Get Started Free
Losmapimod   Get Started Free IBAT inhibitors for the treatment of liver diseases Albireo AB (Gothenburg, SE)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Losmapimod

Drugname Country Document Number Estimated Expiration Related US Patent
Losmapimod Argentina AR101995 2034-09-26   Get Started Free
Losmapimod Australia AU2015320859 2034-09-26   Get Started Free
Losmapimod Brazil BR112017006253 2034-09-26   Get Started Free
Losmapimod Canada CA2962326 2034-09-26   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Colorcon
Boehringer Ingelheim
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.